Focus: Ichnos Glenmark Innovation is a 51-200 person biotech focused on bispecific antibodies across cardiovascular, neurology, immunology, women's health, and respiratory indications. The company operates primarily as a generic and branded pharmaceutical player with legacy products generating modest revenue.
Profile data last refreshed 4d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ichnos Glenmark Innovation to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Revenue anchor (30% of company) but post-LOE generic—provides cash foundation with predictable erosion.
Help build intelligence for Ichnos Glenmark Innovation
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ichnos Glenmark Innovation's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue stream facing imminent loss of exclusivity; represents near-term revenue cliff.
Only product with extended patent protection (LOE 2033); provides longest runway for stable contribution.
Generic post-LOE product with modest Part D spending and limited growth potential.
Minimal revenue contributor in mature respiratory market with generic competition.
74 discontinued, 101 duplicate formulations not shown
+1 more products with revenue data
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+102 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo